Hao Jiang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10448890/publications.pdf

Version: 2024-02-01

33	965	361413	434195
papers	citations	20	31
		h-index	g-index

34	34	34	805
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metabolism of Benzo[a]pyrene in Human Bronchoalveolar H358 Cells Using Liquid Chromatographyâ€“Mass Spectrometry. Chemical Research in Toxicology, 2007, 20, 1331-1341.	3.3	76
2	Fully Validated LC-MS/MS Assay for the Simultaneous Quantitation of Coadministered Therapeutic Antibodies in Cynomolgus Monkey Serum. Analytical Chemistry, 2013, 85, 9859-9867.	6.5	74
3	Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. British Journal of Pharmacology, 2004, 141, 616-623.	5.4	58
4	Competing Roles of Cytochrome P450 1A1/1B1 and Aldoâ^'Keto Reductase 1A1 in the Metabolic Activation of (Â±)-7,8-Dihydroxy-7,8-dihydro-benzo[a]pyrene in Human Bronchoalveolar Cell Extracts. Chemical Research in Toxicology, 2005, 18, 365-374.	3.3	56
5	Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 409-418.	2.8	56
6	Competing Roles of Aldo-Keto Reductase 1A1 and Cytochrome P4501B1 in Benzo[a]pyrene-7,8-diol Activation in Human Bronchoalveolar H358 Cells:Â Role of AKRs in P4501B1 Induction. Chemical Research in Toxicology, 2006, 19, 68-78.	3.3	42
7	Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 769, 169-176.	2.3	39
8	Quantification of benzo[a]pyrene diol epoxide DNA-adducts by stable isotope dilution liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 1369-1380.	1.5	39
9	Practical and Efficient Strategy for Evaluating Oral Absolute Bioavailability with an Intravenous Microdose of a Stable Isotopically-Labeled Drug Using a Selected Reaction Monitoring Mass Spectrometry Assay. Analytical Chemistry, 2012, 84, 10031-10037.	6.5	39
10	Innovative Use of LC-MS/MS for Simultaneous Quantitation of Neutralizing Antibody, Residual Drug, and Human Immunoglobulin G in Immunogenicity Assay Development. Analytical Chemistry, 2014, 86, 2673-2680.	6.5	38
11	Current advances and strategies towards fully automated sample preparation for regulated LCâ€“MS/MS bioanalysis. Bioanalysis, 2014, 6, 2441-2459.	1.5	36
12	Calculation and Mitigation of Isotopic Interferences in Liquid Chromatographyâ€“Mass Spectrometry/Mass Spectrometry Assays and Its Application in Supporting Microdose Absolute Bioavailability Studies. Analytical Chemistry, 2012, 84, 4844-4850.	6.5	35
13	A sensitive and accurate liquid chromatographyâ€“tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine. Journal of Chromatography A, 2012, 1245, 117-121.	3.7	34
14	Important Role of the Dihydrouracil/Uracil Ratio in Marked Interpatient Variations of Fluoropyrimidine Pharmacokinetics and Pharmacodynamics. Journal of Clinical Pharmacology, 2004, 44, 1260-1272.	2.0	32
15	2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays (Part) Tj ETQq1 1 0.784314 rgBT /O	1.5	32
16	Benzo[a]pyrene-7,8-dihydrodiol Promotes Checkpoint Activation and G2/M Arrest in Human Bronchoalveolar Carcinoma H358 Cells. Molecular Pharmacology, 2007, 71, 744-750.	2.3	30
17	Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. Drug Metabolism and Disposition, 2016, 44, 238-249.	3.3	28
18	A Convenient Strategy for Quantitative Determination of Drug Concentrations in Tissue Homogenates Using a Liquid Chromatography/Tandem Mass Spectrometry Assay for Plasma Samples. Analytical Chemistry, 2011, 83, 6237-6244.	6.5	23

#	Article	IF	Citations
19	An exploratory universal LCâ€“MS/MS assay for bioanalysis of hinge region-stabilized human IgG4 mAbs in clinical studies. Bioanalysis, 2014, 6, 1747-1758.	1.5	23
20	Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays. Journal of Immunological Methods, 2015, 416, 94-104.	1.4	23
21	A User-Friendly Robotic Sample Preparation Program for Fully Automated Biological Sample Pipetting and Dilution to Benefit the Regulated Bioanalysis. Journal of the Association for Laboratory Automation, 2012, 17, 211-221.	2.8	20
22	Development and validation of an LCâ€“MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target. Bioanalysis, 2014, 6, 2371-2383.	1.5	19
23	A validated LCâ€“MS/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 973, 1-8.	2.3	19
24	Sensitivity-based analytical approaches to support human absolute bioavailability studies. Bioanalysis, 2014, 6, 497-504.	1.5	19
25	A rugged and accurate liquid chromatographyâ€“tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 921-922, 81-86.	2.3	16
26	A rugged and accurate liquid chromatographyâ€“tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2064-2072.	2.3	14
27	Characterization of ADME properties of [¹⁴C]asunaprevir (BMS-650032) in humans. Xenobiotica, 2016, 46, 52-64.	1.1	13
28	Overcoming interference with the detection of a stable isotopically labeled microtracer in the evaluation of beclabuvir absolute bioavailability using a concomitant microtracer approach. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143, 9-16.	2.8	8
29	A highly sensitive and selective LCâ€“MS/MS method to quantify asunaprevir, an HCV NS3 protease inhibitor, in human plasma in support of pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2016, 119, 145-151.	2.8	6
30	Perspectives on exploring hybrid LBA/LCâ€“MS approach for clinical immunogenicity testing. Bioanalysis, 2019, 11, 1605-1617.	1.5	6
31	Sensitive and accurate liquid chromatographyâ€“tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 17-23.	2.8	5
32	Concerted application of LCâ€“MS and ligand binding assays to better understand exposure of a large molecule drug. Bioanalysis, 2018, 10, 1261-1272.	1.5	3
33	Choosing the right bioanalytical assay platform(s) to support the PK assessment of protein biotherapeutic programs. Bioanalysis, 2015, 7, 1197-1199.	1.5	2